Anti-platelet therapy: phosphodiesterase inhibitors

Anti-cancer Role of Phosphodiesterase-5 Inhibitors

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors.

Theophylline has been used in the treatment of airway diseases, for more than 50 years with benefit thought to be derived from its ability to elicit bronchodilatation. Recent evidence has, however, suggested that theophylline possesses anti-inflammatory activity. The molecular mechanism of action remains unclear, although inhibition of the phosphodiesterase (PDE) enzyme, an enzyme which catalyz...

Theophylline and phosphodiesterase inhibitors.

Correspondence: *Inserm U408, Unité de Pneumologie de l'Hôpital Bichat, Paris, France. ** and Dept of Thoracic Medicine, National Heart and Lung Institute, London, UK. This issue of the European Respiratory Journal starts a series of short reviews based on a Satellite Meeting held during the European Respiratory Society Annual Meeting in Nice in October 1994. The symposium was supported by Byk ...

Novel agents for anti-platelet therapy

Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in the prevention and treatment of cardio-cerebrovascular diseases. Glycoprotein IIb/IIIa antagonists (e.g., abciximab, eptifibatide and tirofiban) have demonstrated good clinical benefits an...

Anti-platelet therapy: ADP receptor antagonists

The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists th...